<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Parry, Nicola</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Grossniklaus, Hans E.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Advances in the Management of Retinoblastoma</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014-12-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">4-6</style></pages><abstract><style  face="normal" font="default" size="100%">There have been 4 periods in the history of retinoblastoma (Rb) since the 18th century: prehistologic, histologic, enucleation, and irradiation/chemotherapy. Since 1964, however, there has been an unprecedented rate of progress in research and treatment in Rb. This article discusses the advances that have occurred in Rb over the past 50 years.</style></abstract><number><style face="normal" font="default" size="100%">43</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>